Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

Decreasing Use of Chemotherapy in Older Patients With Stage III Colon Cancer Irrespective of Comorbidities.

Walter V, Boakye D, Weberpals J, Jansen L, Haefeli WE, Martens UM, Knebel P, Chang-Claude J, Hoffmeister M, Brenner H.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1089-1099. doi: 10.6004/jnccn.2019.7287.

PMID:
31487678
2.

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways.

Huppertz A, Grond-Ginsbach C, Dumschat C, Foerster KI, Burhenne J, Weiss J, Czock D, Purrucker JC, Rizos T, Haefeli WE.

BMC Pharmacol Toxicol. 2019 Aug 29;20(1):53. doi: 10.1186/s40360-019-0331-9.

3.

AgeWell.de - study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients.

Zülke A, Luck T, Pabst A, Hoffmann W, Thyrian JR, Gensichen J, Kaduszkiewicz H, König HH, Haefeli WE, Czock D, Wiese B, Frese T, Röhr S, Riedel-Heller SG.

BMC Geriatr. 2019 Aug 1;19(1):203. doi: 10.1186/s12877-019-1212-1.

4.

[Epidemiology and prevention of heat-related adverse health effects on elderly people].

Herrmann A, Haefeli WE, Lindemann U, Rapp K, Roigk P, Becker C.

Z Gerontol Geriatr. 2019 Aug;52(5):487-502. doi: 10.1007/s00391-019-01594-4. Epub 2019 Jul 25. German.

PMID:
31346679
5.

An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma.

Sauter M, Uhl P, Foerster KI, Mohr I, Höne RT, Merle U, Burhenne J, Haefeli WE.

J Pharm Biomed Anal. 2019 Sep 10;174:633-638. doi: 10.1016/j.jpba.2019.06.015. Epub 2019 Jun 27.

PMID:
31279892
6.

Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE.

Br J Clin Pharmacol. 2019 Jun 20. doi: 10.1111/bcp.14040. [Epub ahead of print]

PMID:
31222796
7.

Use of medication lists: A population-based approach to increase the prevalence of medication lists within a region in Germany. A pre-post study
.

Seidling HM, Mahler C, Straßner C, Strauß B, Bernhard G, Szecsenyi J, Haefeli WE, Wehrmann U.

Int J Clin Pharmacol Ther. 2019 Aug;57(8):375-383. doi: 10.5414/CP203447.

PMID:
31198166
8.

What do laypeople consider 'medication' and are they aware of modulators of a drug's effects?

Send AFJ, Bittmann JA, Dyckhoff G, Haefeli WE, Seidling HM.

Eur J Hosp Pharm. 2018 Jul;25(4):218-221. doi: 10.1136/ejhpharm-2016-001086. Epub 2016 Nov 1.

9.

Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers.

Huppertz A, Ott C, Bruckner T, Foerster KI, Burhenne J, Weiss J, Zorn M, Haefeli WE, Czock D.

Clin Pharmacol Ther. 2019 Jun 1. doi: 10.1002/cpt.1529. [Epub ahead of print]

PMID:
31152598
10.

Process of translation and cross-cultural adaptation of two Australian instruments to evaluate the physician-pharmacist-collaboration in Germany.

Weissenborn M, Krass I, Van C, Dähne A, Ritter CA, Haefeli WE, Seidling HM.

Res Social Adm Pharm. 2019 Mar 23. pii: S1551-7411(18)30978-1. doi: 10.1016/j.sapharm.2019.03.009. [Epub ahead of print]

PMID:
31122799
11.

Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.

Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, Haefeli WE, Krähenbühl S, Mikus G, Inada H, Huwyler J.

Eur J Pharm Sci. 2019 Jul 1;135:77-82. doi: 10.1016/j.ejps.2019.05.010. Epub 2019 May 16.

PMID:
31102650
12.

An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs.

Sauter M, Uhl P, Majewsky M, Fresnais M, Haefeli WE, Burhenne J.

Bioanalysis. 2019 May;11(9):887-898. doi: 10.4155/bio-2018-0322. Epub 2019 May 16.

PMID:
31094209
13.

Structure and Content of Drug Monitoring Advices Included in Discharge Letters at Interfaces of Care: Exploratory Analysis Preceding Database Development.

Morath B, Wien K, Hoppe-Tichy T, Haefeli WE, Seidling HM.

JMIR Med Inform. 2019 Apr 8;7(2):e10832. doi: 10.2196/10832.

14.

Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.

Brings A, Lehmann ML, Foerster KI, Burhenne J, Weiss J, Haefeli WE, Czock D.

Br J Clin Pharmacol. 2019 Jul;85(7):1528-1537. doi: 10.1111/bcp.13934. Epub 2019 May 9.

PMID:
30912163
15.

A follow-up report on potential drug interactions with clementines: Two single case experiments show no effect on CYP3A-dependent midazolam clearance.

Hohmann N, Mikus G, Haefeli WE, Schwenger V, Gattuso G, Barreca D, Weiss J.

Eur J Pharm Sci. 2019 May 15;133:54-58. doi: 10.1016/j.ejps.2019.03.013. Epub 2019 Mar 21.

PMID:
30905614
16.

[New approaches in preventing health risks and excess mortality of older persons during extreme heat].

Becker C, Herrmann A, Haefeli WE, Rapp K, Lindemann U.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 May;62(5):565-570. doi: 10.1007/s00103-019-02927-9. Review. German.

PMID:
30887088
17.

The Role of Adherence Thresholds for Development and Performance Aspects of a Prediction Model for Direct Oral Anticoagulation Adherence.

Ruff C, Koukalova L, Haefeli WE, Meid AD.

Front Pharmacol. 2019 Feb 19;10:113. doi: 10.3389/fphar.2019.00113. eCollection 2019.

18.

[Information Gaps in Package Inserts Cause Insufficient Patient Information on Correct Handling of Transdermal Patches].

Lampert A, Haefeli WE, Seidling HM.

Dtsch Med Wochenschr. 2019 Mar;144(5):e36-e41. doi: 10.1055/a-0722-7419. Epub 2019 Mar 5. German.

PMID:
30836398
19.

Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.

Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE.

Clin Pharmacokinet. 2019 Sep;58(9):1155-1163. doi: 10.1007/s40262-019-00749-1.

PMID:
30828771
20.

Improving eye-drop administration skills of patients - A multicenter parallel-group cluster-randomized controlled trial.

Lampert A, Bruckner T, Haefeli WE, Seidling HM.

PLoS One. 2019 Feb 21;14(2):e0212007. doi: 10.1371/journal.pone.0212007. eCollection 2019.

21.

A Proposal for the Retrospective Identification and Categorization of Older People With Functional Impairments in Scientific Studies-Recommendations of the Medication and Quality of Life in Frail Older Persons (MedQoL) Research Group.

Brefka S, Dallmeier D, Mühlbauer V, von Arnim CAF, Bollig C, Onder G, Petrovic M, Schönfeldt-Lecuona C, Seibert M, Torbahn G, Voigt-Radloff S, Haefeli WE, Bauer JM, Denkinger MD; Medication and Quality of Life Research Group.

J Am Med Dir Assoc. 2019 Feb;20(2):138-146. doi: 10.1016/j.jamda.2018.11.008. Epub 2019 Jan 9.

22.

Evidence for underuse and overuse of antidepressants in older adults: Results of a large population-based study.

Boehlen FH, Freigofas J, Herzog W, Meid AD, Saum KU, Schoettker B, Brenner H, Haefeli WE, Wild B.

Int J Geriatr Psychiatry. 2019 Apr;34(4):539-547. doi: 10.1002/gps.5047. Epub 2019 Jan 8.

PMID:
30623499
23.

Association of generalized anxiety symptoms and panic with health care costs in older age-Results from the ESTHER cohort study.

Hohls JK, Wild B, Heider D, Brenner H, Böhlen F, Saum KU, Schöttker B, Matschinger H, Haefeli WE, König HH, Hajek A.

J Affect Disord. 2019 Feb 15;245:978-986. doi: 10.1016/j.jad.2018.11.087. Epub 2018 Nov 13.

PMID:
30562680
24.

Prediction of Drug-Related Risks Using Clinical Context Information in Longitudinal Claims Data.

Meid AD, Groll A, Heider D, Mächler S, Adler JB, Günster C, König HH, Haefeli WE.

Value Health. 2018 Dec;21(12):1390-1398. doi: 10.1016/j.jval.2018.05.007. Epub 2018 Jun 30.

PMID:
30502782
25.

The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.

Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, Bachleitner-Hofmann T, Roth W, Scherer D, Haefeli WE, Ulrich CM, DeCensi A.

BMC Cancer. 2018 Dec 4;18(1):1210. doi: 10.1186/s12885-018-5126-7.

26.

How to meet patients' individual needs for drug information - a scoping review.

Kusch MK, Haefeli WE, Seidling HM.

Patient Prefer Adherence. 2018 Nov 6;12:2339-2355. doi: 10.2147/PPA.S173651. eCollection 2018. Review.

27.

Patient Experiences With Handling of Analgesic Transdermal Patches and Challenges in Correct Drug Administration: A Pilot Study on Patient Education.

Lampert A, Kessler J, Washington-Dorando P, Bardenheuer HJ, Bocek Eknes EM, Krisam J, Haefeli WE, Seidling HM.

J Patient Saf. 2018 Dec;14(4):e97-e101. doi: 10.1097/PTS.0000000000000538.

PMID:
30451718
28.
29.

A novel superior medication-based chronic disease score predicted all-cause mortality in independent geriatric cohorts.

Quinzler R, Freitag MH, Wiese B, Beyer M, Brenner H, Dahlhaus A, Döring A, Freund T, Heier M, Knopf H, Luppa M, Prokein J, Riedel-Heller SG, Schäfer I, Scheidt-Nave C, Scherer M, Schöttker B, Szecsenyi J, Thürmann P, van den Bussche H, Gensichen J, Haefeli WE.

J Clin Epidemiol. 2019 Jan;105:112-124. doi: 10.1016/j.jclinepi.2018.09.004. Epub 2018 Sep 22.

PMID:
30253216
30.
31.

Plasma Drug Concentrations in Children Receiving Pulmonary Arterial Hypertension Combination Treatment.

Grünig E, Haefeli WE.

Respiration. 2019;97(1):92. doi: 10.1159/000492798. Epub 2018 Sep 13. No abstract available.

PMID:
30212815
32.

Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.

Huppertz A, Werntz L, Meid AD, Foerster KI, Burhenne J, Czock D, Mikus G, Haefeli WE.

Br J Clin Pharmacol. 2018 Dec;84(12):2903-2913. doi: 10.1111/bcp.13757. Epub 2018 Oct 11.

PMID:
30192025
33.

The associations of geriatric syndromes and other patient characteristics with the current and future use of potentially inappropriate medications in a large cohort study.

Muhlack DC, Hoppe LK, Stock C, Haefeli WE, Brenner H, Schöttker B.

Eur J Clin Pharmacol. 2018 Dec;74(12):1633-1644. doi: 10.1007/s00228-018-2534-1. Epub 2018 Aug 29.

PMID:
30159676
34.

Identification, Biosynthesis, and Decapping of NAD-Capped RNAs in B. subtilis.

Frindert J, Zhang Y, Nübel G, Kahloon M, Kolmar L, Hotz-Wagenblatt A, Burhenne J, Haefeli WE, Jäschke A.

Cell Rep. 2018 Aug 14;24(7):1890-1901.e8. doi: 10.1016/j.celrep.2018.07.047.

35.

[Simplifying complex drug therapies : Challenges and solutions].

Wurmbach VS, Lampert A, Schmidt SJ, Bernard S, Thürmann PA; HIOPP-6 Konsortium, Seidling HM, Haefeli WE.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Sep;61(9):1146-1151. doi: 10.1007/s00103-018-2790-3. Review. German.

PMID:
30066132
36.

The impact of potentially inappropriate medication on the development of health care costs and its moderation by the number of prescribed substances. Results of a retrospective matched cohort study.

Heider D, Matschinger H, Meid AD, Quinzler R, Adler JB, Günster C, Haefeli WE, König HH.

PLoS One. 2018 Jul 31;13(7):e0198004. doi: 10.1371/journal.pone.0198004. eCollection 2018.

37.

Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay.

Foerster KI, Huppertz A, Meid AD, Müller OJ, Rizos T, Tilemann L, Haefeli WE, Burhenne J.

Anal Chem. 2018 Aug 7;90(15):9395-9402. doi: 10.1021/acs.analchem.8b02046. Epub 2018 Jul 17.

PMID:
29985592
38.

[Potential Benchmarks for Successful Interdisciplinary Collaboration Projects in Germany: A Systematic Review].

Weißenborn M, Schulz M, Kraft M, Haefeli WE, Seidling HM.

Gesundheitswesen. 2018 Jun 21. doi: 10.1055/a-0592-7184. [Epub ahead of print] German.

PMID:
29929202
39.

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P.

Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi: 10.1080/2162402X.2017.1303584. eCollection 2018.

40.

High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.

Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrich CM, Stabuc B, Puntoni M, Coccia G, Petrera M, Haefeli WE, DeCensi A.

Gastroenterology. 2018 Apr;154(5):1543-1545. doi: 10.1053/j.gastro.2017.12.040. Epub 2018 Mar 8. No abstract available.

41.

Effectiveness of a complex intervention on Prioritising Multimedication in Multimorbidity (PRIMUM) in primary care: results of a pragmatic cluster randomised controlled trial.

Muth C, Uhlmann L, Haefeli WE, Rochon J, van den Akker M, Perera R, Güthlin C, Beyer M, Oswald F, Valderas JM, Knottnerus JA, Gerlach FM, Harder S.

BMJ Open. 2018 Feb 24;8(2):e017740. doi: 10.1136/bmjopen-2017-017740.

42.

Reply to Truffot et al.

Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand MA, Haefeli WE.

Clin Infect Dis. 2018 May 2;66(10):1644-1646. doi: 10.1093/cid/cix1099. No abstract available.

PMID:
29385537
43.

[Electronic decision support to promote medication safety].

Haefeli WE, Seidling HM.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Mar;61(3):271-277. doi: 10.1007/s00103-017-2685-8. Review. German.

PMID:
29340732
44.

Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS.

Majewsky M, Castel D, Le Dret L, Johann P, Jones DT, Pfister SM, Haefeli WE, Burhenne J.

J Pharm Biomed Anal. 2018 Mar 20;151:151-158. doi: 10.1016/j.jpba.2017.12.056. Epub 2017 Dec 28.

PMID:
29328982
45.

Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.

Meid AD, Bighelli I, Mächler S, Mikus G, Carrà G, Castellazzi M, Lucii C, Martinotti G, Nosè M, Ostuzzi G, Barbui C, Haefeli WE.

Ther Adv Psychopharmacol. 2017 Dec;7(12):251-264. doi: 10.1177/2045125317721662. Epub 2017 Aug 28.

46.

Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.

Blank A, Meier K, Urban S, Haefeli WE, Weiss J.

Antivir Ther. 2018;23(3):267-275. doi: 10.3851/IMP3206.

PMID:
29134945
47.

[Benefits of a Medication List from a Citizen's Perspective -A Qualitative Survey].

Strauß B, Seidling HM, Wehrmann U, Szecsenyi J, Haefeli WE, Wensing M, Mahler C.

Gesundheitswesen. 2018 Aug;80(8-09):700-707. doi: 10.1055/s-0043-118478. Epub 2017 Oct 25. German.

PMID:
29069696
48.

Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy.

Foerster KI, Huppertz A, Müller OJ, Rizos T, Tilemann L, Haefeli WE, Burhenne J.

J Pharm Biomed Anal. 2018 Jan 30;148:238-244. doi: 10.1016/j.jpba.2017.10.011. Epub 2017 Oct 16.

PMID:
29055248
49.

Frailty and healthcare costs-longitudinal results of a prospective cohort study.

Hajek A, Bock JO, Saum KU, Matschinger H, Brenner H, Holleczek B, Haefeli WE, Heider D, König HH.

Age Ageing. 2018 Mar 1;47(2):233-241. doi: 10.1093/ageing/afx157.

PMID:
29036424
50.

No, we are not-we keep forgetting the right ventricle.

Ziesenitz VC, Haefeli WE, van den Anker JN, Gorenflo M.

Eur J Clin Pharmacol. 2018 Jan;74(1):141-143. doi: 10.1007/s00228-017-2349-5. Epub 2017 Oct 13. No abstract available.

PMID:
29030645

Supplemental Content

Loading ...
Support Center